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In the past 20 years or so, molecular imaging has been well recognized and numerous imaging probes have been developed along with the advancement and emergence of novel imaging techniques. With exquisite sensitity and specificity, positron emission tomography (PET) became the workhorse in the field, especially for oncological applications. Almost every cancer hallmark summerized by Hanahan and Weinberg (1) can be visualized and evaluated with PET using the corresponding imaging probes.
Angiogenesis has been well recognized as an essential hallmark for tumor growth, invasion and metastasis (2) . Integrin αvβ3 represents a potential molecular marker for angiogenesis due to its significant upregulation on activated endothelial cells but not on quiescent endothelial cells (3) . Most of the currently available integrin-targeted imaging probes are based on Arg-Gly-Asp (RGD) tripeptide sequence because of its high affinity and specificity for integrin αvβ3. However, the application of a molecular imaging probe such as RGD should not be stopped at the level of lesion detection. Instead, the two most commonly suggested uses are the selection of patients for treatments involving angiogenesis and the monitoring of patients receiving such therapies (13) . As integrin αvβ3 is a key player in angiogenesis, it therefore can act as a predictive biomarker to select patients who will most likely benefit from a specific angiogenesis inhibitor, to evaluate treatment response, and to detect emerging resistance. This is particularly important as antiangiogenic therapy usually leads to a delay of tumor growth, rather than tumor shrinkage. Indeed, quite a few preclinical studies reported the use of RGD-based PET tracers for antiangiogenic therapy response monitoring (14, 15) . Some studies suggested that RGD PET could represent the changes of neovascular density and integrin expression during antiangiogenic therapy (16, 17) , while other studies concluded that the tumor uptake of RGD peptide does not necessarily reflect the change of integrin αvβ3 expression upon treatment (18) . The change of ligand binding affinity of integrin αvβ3 at non-activated or activated state further
increases the complexity of image interpretation (3). Consequently, the real potential of RGD PET in therapy response monitoring needs to be confirmed with well-designed clinical investigations.
In this issue of Journal of Nuclear Medicine, we are glad to see that Zhang et al. (19) performed a pilot clinical study to evaluate the predictive value of PET using Alfatide II in patients with glioma. They found that the residual lesions can be visualized clearly with decent contrast to surrounding normal brain tissue. More importantly, Alfatide II PET/CT parameters, especially intra-treatment SUVmax, predicted the tumor sensitivity to concurrent chemoradiotherapy (CCRT). Using this parameter, the effectiveness of CCRT can be predicted as early as three weeks after treatment was initiated. This is the first clinical investigation to apply RGD PET for patient screening and therapy response monitoring. Both baseline SUVmax and intra-treatment SUVmax showed correlation with response to CCRT, with the lesion volume change determined by MRI as the "gold" standard. Compared with baseline SUVmax, intra-treatment SUVmax showed higher sensitivity and specificity. With baseline SUVmax, patient screening can be performed to avoid unnecessary therapy. With intra-treatment parameter, the patients with resistant lesions can be switched to other more sensitive treatment plans. These findings substantiate the value of RGD PET in guiding treatment plan.
In most preclinical studies, the tracer uptake difference between the intra-treatment scan and baseline scan was used as the parameter to reflect tumor response to various therapeutic interventions (14) (15) (16) (17) . However, in this study (19) , the change of SUV
showed no correlation with the responsiveness of the tumor. As the authors stated, this may be due to the irregular tumor margin and intra-tumor cavity caused by surgery. In fact, using one single PET scan to make the decision without baseline subtraction will save the patients from extra radiation exposure. This also reveals the fundamental differences between preclinical studies and clinical trials. The heterogeneity of the target expression in different patients with the same tumor type can be used as a biomarker for patient stratification. In preclinical models, however, it is almost impossible to do so as the variance of imaging target expression in tumor xenografts developed from cancer cell lines is rather limited.
Expression of integrin αvβ3 has been reported to be associated with tumor aggressiveness and metastatic potential in malignant tumors (3) . For sarcoma and glioma, RGD uptake was positively correlated with the grade of tumor differentiation (20, 21) . 
